Drug-Excipient Interaction Occurrences During Solid Dosage Form Development

Preformulation in Solid Dosage Form Development

Volumn , Issue , 2008, Pages 357-436

  Adeyeye, Moji Christianah ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85178645426     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849360862-17     Document Type: Chapter

References (100)

1. Brittain HG. Overview of drug-excipient interactions in pharmaceutical solid dosage forms. Presentation at AAPS Meeting.
2. Committee on Drugs; American Academy of Pediatrics. “Inactive” ingredients in pharmaceutical products. Pediatrics 1997; 99(2):268-7.
3. Byrn SR, Xu W, Eewman AW. Chemical reactivity in solid state pharmaceuticals: formulation implications. Adv Drug Deliv Rev 2001; 48:115-36.
4. Paul IC, Curtin DY. Thermally induced organic reactions in the solid-state. Acc Chem Res 1973; 6:217-25.
5. Ahlneck C, Zografi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid-state. Int J Pharm 1990; 62:87-95.
6. Baxter JG, Robeson CE. Crystalline aliphatic esters of vitamin A. J Am Chem Soc 1942; 64:2407-10.
7. Guillory JK, Higuchi T. Solid-state stability of some crystalline vitamin A compounds. J Pharm Sci 1962; 5:100-5.
8. Xu W. Investigation of Solid-State Stability of Selected Bioactive Compounds. Ph.D. thesis, Purdue University, West Lafayette, IN, 1997:47 907-1333.
9. Lin CT, Perrier P, Clay GG, Sutton PA, Byrn SR. Solid-state photooxidation of 21-cortisol tert-butylacetate to 21-cortisone tert-butylacetate. J Org Chem 1982; 47:2978-81.
10. Byrn SR, Sutton PA, Tobias B, Frye J, Main P. Crystal structure, solid-state NMR spectra, and oxygen reactivity of five crystal forms of prednisolone tertbutylacetate. J Am Chem Soc 1988; 110:1609-14.
11. Hausin RJ, Codding PW. Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors. J Med Chem 1991; 34:511-7.
12. Lai MC, Hageman MJ, Schowen RL, Borchardt RL, Topp EM. Chemical stability of peptides in polymers. 1. Effect of water on peptide deamidation in poly(vinyl alcohol) and poly(vinyl pyrrolidone) matrixes. J Pharm Sci 2000; 88:1073-80.
13. Lai MC, Hageman MJ, Schowen RL, Borchardt RL, Laird BB, Topp EM. Chemical stability of peptides in polymers. 2. Discriminating between solvent and plasticizing effects of water on peptide deamination in poly(vinylpyrrolidone). J Pharm Sci 2000; 88:1081-9.
14. Serajuddin ATM, Thakur AB, Ghoshal RN, et al. Selection of solid dosage form composition through drug-excipient compatibility testing. J Pharm Sci 1999; 88:696-704.
15. Monkhouse DC, Maderich A. Whither compatibility testing? Drug Dev Ind Pharm 1989; 15:2115-30.
16. Botha SA, Lotter AP. Compatibility study between atenolol and tablet excipients using differential scanning calorimetry. Drug Dev Ind Pharm 1990; 16(12):1945.
17. Venkataram S, Khohlokwane M, Wallis SH. Evaluation of the compatibility of ketorolac tromethamine with selected polymers and common tablet excipients by thermal and isothermal stress testing. Drug Dev Ind Pharm 1995; 21:847-55.
18. Kandarapu R, Grover V, Chawla HPS, Garg S. Evaluation of the compatibility of ketorolac tromethamine with selected polymers and common tablet excipients by thermal and isothermal stress testing. STP Pharm Sci 2001; 11:449-57.
19. Mura P, Manderioli A, Bramanti G, Furlanetto S, Pinzauti S. Utilization of differential scanning calorimetry as a screening technique to determine the compatibility of ketoprofen with excipients. Int J Pharm 1995; 119:71-9.
20. Mura P, Faucci MT, Manderioli A, Bramanti G, Ceccarelli L. Compatibility study between ibuproxam and pharmaceutical excipients using differential scanning calorimetry, hot-stage microscopy and scanning electron microscopy. J Pharm Biom Anal 1998; 18:151-63.
21. Botha SA, Lotter AP. Compatibility study between naproxen and tablet excipients using differential scanning calorimetry. Drug Dev Ind Pharm 1990; 16(4):673.
22. McDaid FM, Barker SA, Fitzpatrick S, Petts CR, Craig DQM. Further investigations into the use of high sensitivity differential scanning calorimetry as a means of predicting drug-excipient interactions. Int J Pharm 2003; 252: 235-40.
23. Balestrieri F, Magri AD, Magri AL, Marini D, Sacchini A. Application of differential scanning calorimetry to the study of drug-excipient compatibility, Thermochimica Acta 1996; 285:337.
24. Morris KR, Newman AW, Bugay DE, et al. Characterization of humiditydependent changes in crystal properties of a new HMG-CoA reductase inhibitor in support of its dosage form development. Int J Pharm 1994; 108: 195-206.
25. Carstensen JT, Johnson JB, Valentine W, Vance JJ. Extrapolation of appearance of tablets and powders from accelerated storage tests. J Pharm Sci 1964; 53:1050-4.
26. Gu L, Strickley RG, Chi L, Chowhan ZT. Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation. Pharm Res 1990; 7:379-83.
27. Verma RK, Garg S. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J Pharm Biomed Anal 2004; 35:449-58.
28. Verma RK, Garg S. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing. J Pharma Biomed Anal 2005; 38:633-44.
29. Adeyeye MC, Mwangi E, Katondo B, Jain A, Ichikawa H, Fukumori Y. Dissolution stability studies of suspensions of prolonged-release diclofenac microcapsules prepared by the Wurster process: I. Eudragit-based formulation and possible drug-excipient interaction. J Microencapsul 2005; 22(4): 333-42.
30. Liu J, Xiao Y, Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci 2004; 93(1):132-43.
31. Greenhalgh D, Williams A, York TP. Solubility parameters as predictors of miscibility in solid disperisons. J Pharm Sci 1999; 88:1182-90.
32. Suzuki H, Sunada H. Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem Pharm Bull 1998; 46:6(3):482-7.
33. Katpally S, Ghorab S, Madura MK, Mosher JD, Thompson JD, Adeyeye MC. Characterization of Bile Salt/SBE-7 b-Cyclodextrin Interactions Using Isothermal Microcalorimetry. MS thesis, Duquesne University.
34. Wissing S, Craig DQM, Barker SA, Moore WD. An investigation into the use of stepwise isothermal high sensitivity DSC as a means of detecting drugexcipient incompatibility. Int J Pharm 2000; 199:141-50.
35. Beezer AE, Loch W, Mitchell JC, et al. An investigation of dilute aqueous solution behavior of poly(oxyethy1ene) þ poly(oxypropy1ene) þ poly (oxyethy1ene) block copolymers. Langmuir 1994; 10:4001-5.
36. Mura P, Furlanetto S, Cirri M, Maestrelli F, Marras AM, Pinzauti S. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and d-optimal mixture experimental design. J Pharm Biomed Anal 2005; 37:65-71.
37. Takahashi Y, Nakashima K, Ishihara T, Nakagawa H. Polymorphism of fostedil: characterization and polymorphic change by mechanical treatments. Drug Dev Indust Pharm 1985; 11:1543-63.
38. Qiu Z, Stowell JG, Cao W, Morris KR, Byrn SR, Carvajal MT. Effect of milling and compression on the solid-state Maillard reaction. J Pharm Sci 2005; 94(11):2568-80.
39. Roy S, Alexander KS, Riga AT, Chatterjee K. Characterization of physical mixtures and directly compressed tablets of sulfamerazine polymorphs: implications on in vitro release characteristics. J Pharm Sci 2003; 92(4):747-59.
40. Sun C, Grant DJ. Influences of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm Res 2001; 18:274-80.
41. Wang LH, Chowhan ZT. Drug-excipient interactions resulting from powder mixin. Part 5. Role of sodium lauryl sulfate. Int J Pharm 1990; 60: 61-78.
42. Ong JT, Chowhan ZT, Samuels GJ. Drug-excipient interactions resulting from powder mixin. Part 6. Role of various surfactants. Int J Pharm 1993; 96: 231-42.
43. Airaksinen S, Karjalainen M, Shevchenko A, et al. Role of water in the physical stability of solid dosage formulations. J Pharm Sci 2005; 94(10): 2147-65.
44. Sing KSW, Everett DH, Haul RAW, et al. Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity (recommendations). Pure Appl Chem 1985; 57:603-19.
45. Rouquerol F, Rouquerol J, Sing K. Introduction, assessment of mesoporosity and general conclusions and recommendations. In: Rouquerol F, Rouquerol J, Sing K, eds. Adsorption by Powders and Porous Solids. London, Great Britain: Academic Press, 1999:1-26, 191-218, 439-47.
46. Salameh AK, Taylor LS. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J Pharm Sci 2006; 95(2):446-61.
47. Otsuka M, Matsuda Y. The effect of humidity on hydration kinetics of mixtures of nitrofurantoin anhydride and diluents. Chem Pharm Bull 1994; 42: 156-9.
48. Adeyeye, et al. Evaluation of crystallinity and drug release stability of directly compressed theophylline hydrophilic matrix tablets stored under varied moisture conditions. Int J Pharm 1995; 116:65-75.
49. Byrn SR, Lin CT. The effect of crystal packing and defects on desolvation of hydrate crystals of caffeine and L-(2)-1,4-cyclohexadiene-1-alanine. J Am Chem Soc 1976; 98:4004-5.
50. Wells JI. Pharmaceutical Preformulation: the Physical and Chemical Properties of Drug Substances. Chichester: Ellis Horwood, 1988.
51. Chen X, Ulrich J, Griesser J, et al. Analysis of the acid-base reaction between solid indomethacin and sodium bicarbonate using infrared spectroscopy, X-ray powder diffraction, and solid state nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 2005; 38:670-7.
52. Usui F, Carstensen JT. Interactions in the solid-state. I. Interactions of sodium bicarbonate and tartaric acid under compressed conditions. J Pharm Sci 1985; 74:1293-7.
53. Wright L, Carstensen JT. Interactions in the solid-state. II. Interaction of sodium bicarbonate with substituted benzoic acids in the presence of moisture. J Pharm Sci 1986; 75:546-51.
54. Huang WX, Desai M, Tang Q, Yang R, Vivilecchia RV, Joshi Y. Elimination of metformin-croscarmellose sodium interaction by competition. Int J Pharm 2006; 27:311(1-2):33-9.
55. Hollenbeck RG, Mitrevej KT, Fan AC. Estimation of the extent of drug-excipient interactions involving croscarmellose sodium. J Pharm Sci 1983; 72:325-7.
56. Crowley P, Martini L. Drug-excipient interactions. Pharm Tech Eur 2001; 26-34.
57. Jenquin MR, Liebowitz SM, Sarabia RE, McGinity JW. Physical and chemical factors influencing the release of drugs from acrylic resin films, J Pharm Sci 1990; 79(9):811-6.
58. Khalil E, Sallam A. Interaction of two diclofenac acid salts with copolymers of ammoniomethacrylate: effect of additives and release profiles. Drug Dev Ind Pharm 1999; 25(4):419-27.
59. Breitkreutz J. Leakage of enteric (Eudragit_ L)-coated dosage forms in simulated gastric juice in the presence of poly(ethylene glycol). J Control Rel 2000; 67:79-88.
60. Thakur AB, Morris K, Grosso JA, et al. Mechanism and kinetics of metal ion-mediated degradation of fosinopril sodium. Pharm Res 1993; 10(6): 800-9.
61. Wirth DD, Baertschi SW, Johnson RA, et al. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci 1998; 87: 31-9.
62. Troup AE, Mitchner H. Degradation of phenylephrine hydrochloride in tablet formulations containing aspirin. J Pharm Sci 1964; 53:375-9.
63. Jacobs AL, Dilatush AE, Weinstein S, Windheuser JJ. Formation of acetylcodeine from aspirin and codeine. J Pharm Sci 1966; 55:893-5.
64. Koshy KT, Troup AE, Duvall RN, Conwell RN, Shankle LL. Acetylation of acetaminophen in tablet formulations containing aspirin. J Pharm Sci 1967; 56:1117-21.
65. Broadhead J, Edmond-Rouan SK, Rhodes CT. The spray drying of pharmaceuticals. Drug Dev Ind Pharm 1996; 22:813-22.
66. Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue plasminogen activator. Pharm Res 1994; 11:12-20.
67. Mumenthaler M, Leuenberger H. Atmospheric spray-freeze-drying: a suitable alternative in freeze-drying technology. Int J Pharm 1991; 72:97-110.
68. Winters MA, Knutson BL, Debenedetti PG, et al. Precipitation of proteins in supercritical carbon dioxide. J Pharm Sci 1996; 85:586-94.
69. Tzannis ST, Prestrelski SJ. Activity-stability considerations of trypsinogen during spray drying: effects of sucrose. J Pharm Sci 1999; 88(3):351-9.
70. Costantino HR, Carrasquillo KG, Cordero RA, Mumenthaler M, Hsu C, Griebenow K. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci 1998; 87(11): 1412-20.
71. D’Souza AJM, Schowen RL, Borchardt RT, Salisbury JS, Munson EJ, Topp EM. Reaction of a peptide with polyvinylpyrrolidone in the solid state. J Pharm Sci 2003; 92(3):585-93.
72. Akers MJ, Lach JL, Fischer LJ. Alterations in the absorption of dicoumarol by various excipient materials. J Pharm Sci 1973; 62:391-5.
73. Ghorab MK. A Dissertation Presented to Graduate School of Pharmaceutical Sciences. Duquesne University, Sept 2001:7.
74. Krenn M, Gamcsik MP, Vogelsang GB, Colvin OM, Leong KW. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-b-cyclodextrin. J Pharm Sci 1992; 81:685-9.
75. Badawy SIF, Ghorab MM, Adeyeye CM. Characterization and biovailability of danazol-hydroxypropyl-b-cyclodextrin. Int J Pharm 1996; 128:45-54.
76. Jain AC, Aungst BJ, Adeyeye CM. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether-cyclodextrin (SBE 7 cyclodextrin) complexes. J Pharm Sci 2002; 91(7):1659-68.
77. Ghorab MK, Adeyeye MC. Enhanced bioavailability of process-induced fastdissolving ibuprofen cogranulated with b-cyclodextrin. J Pharm Sci 2003; 92(8):1691-7.
78. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86(2):147-62.
79. Gerloczy A, Fonagy A, Keresztes P, Perlaky L, Szejtli J. Absorption, distribution, excretion and metabolism of orally administered 14C-betacyclodextrin in rat. Arzneim-Forsch 1985; 35(7):1042-47.
80. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14:556-67.
81. Jackson K, Young D, Pant S. Drug-excipient interactions and their effect on absorption. Research focus: reviews. PSTT 2000; 3(10):336-45.
82. Shargel L, Yu ABC, eds. Applied Biopharmaceutics and Pharmacokinetics. 2nd ed. Norwalk, CT: Appleton-Century-Crofts, 1985.
83. Singh P, et al. Effect of inert tablet ingredients on drug absorption, I. Effect of polyethylene glycol 4000 on the intestinal absorption of four barbiturates. J Pharm Sci 1966; 55:63-8.
84. Yen JKC. The dissolution rate principle in practical tablet formulation. Can Pharm J 1964; 26:493-9.
85. Asakawa Y, et al. Drug-disintegrant interactions: binding of oxymorphone derivatives. J Pharm Sci 1981; 70:709-11.
86. Llabres M, et al. Quantification of the effect of excipients on bioavailability by means of response surfaces, I: amoxicillin in fat matrix. J Pharm Sci 1982; 71:924-7.
87. Llabres M, et al. Quantification of the effect of excipients on bioavailability by means of response surfaces, II: amoxicillin in fat-silica matrix. J Pharm Sci 1982; 71:927-30.
88. Llabres M, et al. Quantification of the effect of excipients on bioavailability by means of response surfaces, III: in vivo-in vitro correlations. J Pharm Sci 1982; 71:930-2.
89. Sugimoto M, et al. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using watersoluble polymer. Int J Pharm 1998; 160:11-9.
90. Bhattacharyya M, et al. Formulation and in vitro-in vivo characterization of solid dispersions of piroxicam. Drug Dev Ind Pharm 1993; 19:739-47.
91. Fawaz F, et al. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits. Int J Pharm 1996; 132:271-5.
92. Guyot M, et al. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions. Int J Pharm 1995; 123:53-63.
93. Veiga MD, et al. Dissolution behaviour of drugs from binary and ternary systems. Int J Pharm 1993; 93:215-20.
94. Ghosh LK, et al. Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Drug Dev Ind Pharm 1998; 24:473-7.
95. Owusu-Ababio G, et al. Comparative dissolution studies for mefenamic acid-polyethylene glycol solid dispersion systems and tablets. Pharm Dev Technol 1998; 3:405-12.
96. Chowdary KPR, Suresh Babu KVV. Dissolution, bioavailability and ulcerogenic studies on solid dispersions of indomethacin in water soluble cellulose polymers. Drug Dev Ind Pharm 1994; 20:799-813.
97. Kortejarvi H, Yliperttula M, Dressman JB, et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J Pharm Sci 2005; 94(8):1617-35.
98. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000; 89:429-42.
99. Rege BD, Yu LX, Hussain AS, Polli JE. Effect of common excipients on Caco-2 transport of lowpermeability drugs. J Pharm Sci 2001; 90:1776-86.
100. Yu LX, Wang JT, Hussain AS. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. AAPS PharmSci 2002; 4:E1.